MVMarcelo Siqueira Valle

Marcelo Siqueira Valle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcelo Siqueira Valle has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer’s (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives

    by Géssica Oliveira Mendes, Lucas Diego Pereira Bento, Thiago Malverde de Oliveira, Deyse Brito Barbosa, Guilherme Saraiva Tsui, Ellen Nunes Gomes, Raphaela Oliveira Sales, Mateus Silva de Castro Rocha, Michel Pires da Silva, Tiago Alves de Oliveira, et al.

    Background/Objectives: Alzheimer’s disease (AD) is a progressive, multifactorial neurodegenerative condition characterized by neurofibrillary tangles, neuronal loss, cognitive impairment, and accumulation of β-amyloid plaques. Considering the limitations of current treatments, which present adverse effects and only alleviate symptoms without modifying disease progression, there is an urgent need for new therapeutic approaches. This study aimed to investigate the neuroprotective potential of synthetic derivatives of (1E,4E)-1,5-bis[(het)aryl]penta-1,4-dien-3-ones, focusing on the inhibition of the cholinesterase enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), targets directly related to the cholinergic deficit observed in AD. Methods: The compounds were initially synthesized by aldol condensation reactions, with subsequent physicochemical characterization. They were then subjected to in silico assays that demonstrated high binding affinity to the active sites of AChE and BChE. The derivatives were evaluated in vitro for their inhibitory activity on these enzymes and in vivo in an experimental model of AD induced by streptozotocin in Wistar rats. Results: The synthesized derivatives showed favorable predicted interactions with the active sites of AChE and BChE, supporting their potential as cholinesterase inhibitors. In vitro assays demonstrated inhibitory activity against both enzymes, with selected derivatives showing improved activity compared with the parent scaffold. In the in vivo model, treatment with the selected compounds was associated with neuroprotective effects, suggesting preservation of nervous tissue integrity under AD-like conditions. Conclusions: These findings indicate that derivatives may represent promising candidates for further investigation as multitarget agents for AD. The study reinforces the relevance of integrating organic synthesis, molecular modeling, enzymatic assays, and in vivo evaluation in the search for new therapeutic strategies for neurodegenerative diseases.

  • Open Access

    Integrative In Silico and In Vivo Evidence of Quercetin as a Multitarget Neuroprotective Agent in Alzheimer’s Disease

    by Thiago Malverde de Oliveira, Lucas Diego Pereira Bento, Isabela Santos de Melo Wiermann, Bianca de Souza Fonseca, Guilherme Saraiva Tsui, Carolina Jayne Pereira de Jesus, Raphaela Oliveira Sales, Mateus Antonio Pereira Prado, Mateus Silva de Castro, João Pedro Reis Moura, et al.

    Alzheimer’s disease requires therapeutic strategies targeting multiple pathological mechanisms. This study investigates the neuroprotective potential of quercetin using an integrated approach combining in silico modeling and in vivo validation. Computational analyses examined the binding behavior of quercetin toward three key enzymes implicated in disease pathophysiology: acetylcholinesterase, butyrylcholinesterase, and beta-secretase 1. Molecular dynamics simulations reveal consistent interaction patterns and stable binding profiles across independent trajectories. For experimental validation, Wistar rats with surgically induced Alzheimer’s disease were orally treated with quercetin (30 mg/kg) for 5 weeks. Histological and immunohistochemical analyses of the hippocampus and subventricular zone evaluated neuronal density and astrocytic activation using glial fibrillary acidic protein and vimentin markers. Computational results supported the multitarget potential of quercetin through stable enzyme interactions. Consistently, in vivo assays demonstrated increased neuronal density and reduced astrocytic marker expression, suggesting a protective modulation of neuroinflammatory processes. These findings highlight quercetin as a promising scaffold for multitarget therapeutic strategies aimed at mitigating the progression of Alzheimer’s disease.

  • Open Access

    Silodosin as a Novel Inhibitor of Acetylcholinesterase, Butyrylcholinesterase, and BETA-Secretase 1: In Vitro and In Silico Studies

    by Deyse B. Barbosa, Lucas Matheus G. de Oliveira, Géssica O. Mendes, David B. Costa Junior, Tiago A. de Oliveira, Michel P. da Silva, Laila Cristina M. Damázio, Eduardo H. B. Maia, Daniel Luciano Falkoski, Isabela F. de S. Marra, et al.

    Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the leading cause of cognitive decline in older adults. Several biomarkers of AD have been identified, but its pathogenesis has not yet been completely elucidated. One of the most relevant hypotheses proposed to explain the cognitive impairment caused by this disease is the cholinergic hypothesis, which postulates that loss of cholinergic neurons is one of its causes and that the subsequent reduction of acetylcholine levels in the synaptic cleft can be compensated through the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Another well-known hypothesis is the amyloid-beta hypothesis, which explains the disease as being caused by the formation and accumulation of amyloid plaques in a cascade of enzymatic events starting with the cleavage of an amyloid precursor protein (APP) by beta-secretase 1 (BACE-1). Previous studies have shown that silodosin has the structural requirements for the inhibition of those three enzymes (AChE, BuChE, and BACE-1), which suggests that it can be useful as a multitarget candidate to treat Alzheimer patients. This study aims to assess the effect of silodosin on cellular viability, measure the inhibitory activity against AChE, BuChE, and BACE-1, and evaluate the molecular behavior of all three inhibitor-enzyme systems by molecular dynamics (MD) simulations. Cell viability assays through the MTT method showed that silodosin concentrations of less than 10 μM are safe to be used. Enzymatic assays revealed AChE inhibitory activity at high micromolar levels (IC50 >500.0 μM) but inhibited BuChE at low micromolar levels (IC50 = 3.02 ± 0.05 μM). BACE-1 inhibition assays have shown significant reduction at three micromolar. MD simulations demonstrated that silodosin promotes late stabilization of the AChE complex, but the simulations involving BuChE and BACE-1 revealed that the compound promotes system stabilization at early stages and has the structural requirements to inhibition.


  • Flotation of carbonates from dolomitic iron ore: synthesis, characterization and application of a novel N,N-bis(2-hydroxyethyl)oleamide collector

    by Guilherme Otávio dos Santos, Aline Alves da Silva, Lucas José da Silva Nascimento, Maria Fernanda Reis Souza, Rafaela de Oliveira Teixeira Menezes, Francielle Christine Cunha Andrade, Marcelo Siqueira Valle, Antônio Eduardo Clark Peres, Gilberto Rodrigues da Silva


  • Exploring the two-photon absorption response in short π-chain organic compounds: Hydrazones and pyrazolines derivatives

    by Raiane S. Araújo, Luis M.G. Abegão, Leandro H.Z. Cocca, Aline A. da Silva, Marcelo S. Valle, José J. Rodrigues, Cleber R. Mendonça, Leonardo De Boni, Márcio A.R.C. Alencar


  • Open Access

    Identification of Potential Multitarget Compounds against Alzheimer’s Disease through Pharmacophore-Based Virtual Screening

    by Géssica Oliveira Mendes, Moysés Fagundes de Araújo Neto, Deyse Brito Barbosa, Mayra Ramos Do Bomfim, Lorena Silva Matos Andrade, Paulo Batista de Carvalho, Tiago Alves de Oliveira, Daniel Luciano Falkoski, Eduardo Habib Bechelane Maia, Marcelo Siqueira Valle, et al.

    Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive loss of cognitive functions, and it is the most prevalent type of dementia worldwide, accounting for 60 to 70% of cases. The pathogenesis of AD seems to involve three main factors: deficiency in cholinergic transmission, formation of extracellular deposits of β-amyloid peptide, and accumulation of deposits of a phosphorylated form of the TAU protein. The currently available drugs are prescribed for symptomatic treatment and present adverse effects such as hepatotoxicity, hypertension, and weight loss. There is urgency in finding new drugs capable of preventing the progress of the disease, controlling the symptoms, and increasing the survival of patients with AD. This study aims to present new multipurpose compounds capable of simultaneously inhibiting acetylcholinesterase (AChE), butyrylcholinesterase (BChE)—responsible for recycling acetylcholine in the synaptic cleft—and beta-secretase 1 (BACE-1)—responsible for the generation of amyloid-β plaques. AChE, BChE, and BACE-1 are currently considered the best targets for the treatment of patients with AD. Virtual hierarchical screening based on a pharmacophoric model for BACE-1 inhibitors and a dual pharmacophoric model for AChE and BChE inhibitors were used to filter 214,446 molecules by QFITBACE > 0 and QFITDUAL > 56.34. The molecules selected in this first round were subjected to molecular docking studies with the three targets and further evaluated for their physicochemical and toxicological properties. Three structures: ZINC45068352, ZINC03873986, and ZINC71787288 were selected as good fits for the pharmacophore models, with ZINC03873986 being ultimately prioritized for validation through activity testing and synthesis of derivatives for SAR studies.


  • Polyketides from Fungi

    by Christiane Contigli, Marcelo Siqueira Valle, Sílvia Catarina Salgado Oloris, Lúcia Pinheiro Santos Pimenta, Jacqueline Aparecida Takahashi


  • Comparing two-photon absorption of chalcone, dibenzylideneacetone and thiosemicarbazone derivatives

    by Raiane S. Araújo, Lucas F. Sciuti, Leandro H.Z. Cocca, Thaís O. Lopes, Aline A. Silva, Luis M.G. Abegão, Marcelo S. Valle, José J. Rodrigues Jr, Cleber R. Mendonça, Leonardo De Boni, et al.


  • Synthesis and characterization of 1,3,5-triarylpyrazol-4-ols and 3,5-diarylisoxazol-4-ols from chalcones and theoretical studies of the stability of pyrazol-4-ol toward acid dehydration

    by Edna Carolina Cipagauta Esquivel, Virgínia Camila Rufino, Matheus Henrique Trindade Nogueira, Ana Carolina Carbonaro Souza, Josefredo Rodriguez Pliego Júnior, Marcelo Siqueira Valle


  • Open Access

    Nonlinear Optical Study in a Set of Dibenzylideneacetone Derivatives with Potential for Optical Frequency Conversion

    by Francisco A. Santos, Luis M. G. Abegão, Ruben D. Fonseca, Aline M. Alcântara, Cleber R. Mendonça, Márcio A. R. C. Alencar, Marcelo S. Valle, Kenji Kamada, Leonardo De Boni, José J. Rodrigues

    The search for advanced optical materials, in particular, materials with nonlinear optical responses, has, in the last years, experienced substantial growth due to their vast applications in the photonics field. One of those applications is ultra-fast optical frequency conversion, in the optics communications field. Organic compounds have emerged as promising candidates for raw materials to develop nonlinear optical devices, such as optical converters, due to their intrinsic ultra-fast electronic responses. Also, the easy tailoring of organic molecular structures makes organic materials much more appealing than the inorganic ones. In this work, we have performed a linear and nonlinear optical characterization of a set of dibenzylideneacetone derivatives. The nonlinear optical responses investigated correspond to second- and third-order nonlinear processes, namely, first electronic molecular hyperpolarizability and two-photon absorption cross-section, respectively. The value of the first electronic molecular hyperpolarizability, up to 52 cm4·statvolt−1, could be considered a robust value when compared to the short-sized π-electron backbone length of the studied compounds. Such results suggest that these compounds exhibit the potential to be used as optical frequency converters. Quantum chemical calculations were used to predict the theoretical value of the first molecular hyperpolarizability, as well as to simulate the one- and two-photon absorption spectra for all compounds.